{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T20:23:22Z","timestamp":1787775802198,"version":"build-2784847793"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,5,5]],"date-time":"2017-05-05T00:00:00Z","timestamp":1493942400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Janssen Scientific Affairs, LLC"}],"content-domain":{"domain":["clinicalkey.jp","schres-journal.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.schres.2017.05.005","type":"journal-article","created":{"date-parts":[[2017,6,8]],"date-time":"2017-06-08T00:30:34Z","timestamp":1496881834000},"page":"39-46","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Comparison of long-acting and oral antipsychotic treatment effects in patients with schizophrenia, comorbid substance abuse, and a history of recent incarceration: An exploratory analysis of the PRIDE study"],"prefix":"10.1016","volume":"194","author":[{"given":"H.","family":"Lynn Starr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Bermak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lian","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9991-6905","authenticated-orcid":false,"given":"Larry","family":"Alphs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.schres.2017.05.005_bb0005","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.4088\/JCP.13m08965","volume":"75","author":"Alphs","year":"2014","journal-title":"J. Clin. Psychiatry."},{"issue":"5","key":"10.1016\/j.schres.2017.05.005_bb0010","doi-asserted-by":"crossref","first-page":"554","DOI":"10.4088\/JCP.14m09584","article-title":"Real-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia: a randomized, open-label, review board\u2013blinded 15-month study","volume":"76","author":"Alphs","year":"2015","journal-title":"J. Clin. Psychiatry."},{"key":"10.1016\/j.schres.2017.05.005_bb0015","series-title":"Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision","first-page":"154","author":"American Psychiatric Association","year":"2000"},{"issue":"3","key":"10.1016\/j.schres.2017.05.005_bb0020","doi-asserted-by":"crossref","first-page":"453","DOI":"10.4088\/JCP.v67n0317","article-title":"Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care","volume":"67","author":"Ascher-Svanum","year":"2006","journal-title":"J. Clin. Psychiatry."},{"key":"10.1016\/j.schres.2017.05.005_bb0025","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1471-244X-10-11","article-title":"Involvement in the US criminal justice system and cost implications for persons treated for schizophrenia","volume":"10","author":"Ascher-Svanum","year":"2010","journal-title":"BMC Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2017.05.005_bb0030","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/00005053-199304000-00003","article-title":"Substance abuse in schizophrenia: service utilization and costs","volume":"181","author":"Bartels","year":"1993","journal-title":"J. Nerv. Ment. Dis."},{"issue":"8","key":"10.1016\/j.schres.2017.05.005_bb0035","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1001\/jamapsychiatry.2015.0241","article-title":"Efficacy and safety of the 3-month formulation of paliperidone palmitate vs placebo for relapse prevention of schizophrenia: a randomized clinical trial","volume":"72","author":"Berwaerts","year":"2015","journal-title":"JAMA Psychiatry"},{"issue":"2\u20133","key":"10.1016\/j.schres.2017.05.005_bb0040","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.drugalcdep.2006.09.002","article-title":"Initial evidence for the reliability and validity of a \u201cLite\u201d version of the Addiction Severity Index","volume":"87","author":"Cacciola","year":"2007","journal-title":"Drug Alcohol Depend."},{"issue":"3","key":"10.1016\/j.schres.2017.05.005_bb0045","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1159\/000355267","article-title":"Treatment for outpatients with comorbid schizophrenia and substance use disorders: a review","volume":"20","author":"De Witte","year":"2013","journal-title":"Eur. Addict. Res."},{"issue":"1\u20133","key":"10.1016\/j.schres.2017.05.005_bb0055","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.schres.2011.02.024","article-title":"Schizophrenia and serious violence: a clinical-profile analysis incorporating impulsivity and substance-use disorders","volume":"130","author":"Dumais","year":"2011","journal-title":"Schizophr. Res."},{"issue":"4","key":"10.1016\/j.schres.2017.05.005_bb0060","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1093\/schbul\/23.4.637","article-title":"Determinants of medication compliance in schizophrenia: empirical and clinical findings","volume":"23","author":"Fenton","year":"1997","journal-title":"Schizophr. Bull."},{"issue":"6","key":"10.1016\/j.schres.2017.05.005_bb0065","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1034\/j.1600-0447.2002.02209.x","article-title":"Schizophrenia in homeless persons: a systematic review of the literature","volume":"105","author":"Folsom","year":"2002","journal-title":"Acta Psychiatr. Scand."},{"issue":"5","key":"10.1016\/j.schres.2017.05.005_bb0070","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/YIC.0b013e32833948fa","article-title":"Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study","volume":"25","author":"Gopal","year":"2010","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"6","key":"10.1016\/j.schres.2017.05.005_bb0075","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s10597-010-9362-9","article-title":"Criminal justice system involvement among people with schizophrenia","volume":"47","author":"Greenberg","year":"2011","journal-title":"Community Ment. Health J."},{"issue":"1","key":"10.1016\/j.schres.2017.05.005_bb0080","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0165-1781(01)00250-5","article-title":"Substance abuse and suicidality in schizophrenia: a common risk factor linked to impulsivity","volume":"102","author":"Gut-Fayand","year":"2001","journal-title":"Psychiatry Res."},{"issue":"4","key":"10.1016\/j.schres.2017.05.005_bb0085","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1177\/2045125312474019","article-title":"Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review","volume":"3","author":"Higashi","year":"2013","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/j.schres.2017.05.005_bb0090","series-title":"Public Health Behind Bars: From Prisons to Communities","first-page":"461","article-title":"Providing transition and outpatient services to the mentally ill released from correctional institutions","author":"Hoge","year":"2007"},{"issue":"2\u20133","key":"10.1016\/j.schres.2017.05.005_bb0095","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.schres.2009.10.026","article-title":"Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study","volume":"116","author":"Hough","year":"2010","journal-title":"Schizophr. Res."},{"issue":"10","key":"10.1016\/j.schres.2017.05.005_bb0100","doi-asserted-by":"crossref","first-page":"892","DOI":"10.4088\/JCP.v63n1007","article-title":"Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature","volume":"63","author":"Lacro","year":"2002","journal-title":"J. Clin. Psychiatry."},{"issue":"12","key":"10.1016\/j.schres.2017.05.005_bb0105","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1176\/ps.2010.61.12.1239","article-title":"Medication adherence and hospitalization among patients with schizophrenia treated with antipsychotics","volume":"61","author":"Lang","year":"2010","journal-title":"Psychiatr. Serv."},{"issue":"1","key":"10.1016\/j.schres.2017.05.005_bb0110","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1744-859X-12-22","article-title":"Long-acting injectable paliperidone palmitate versus oral paliperidone extended release: a comparative analysis from two placebo-controlled relapse prevention studies","volume":"12","author":"Markowitz","year":"2013","journal-title":"Ann. General Psychiatry"},{"key":"10.1016\/j.schres.2017.05.005_bb0115","series-title":"The Prevalence of Co-Occurring Mental Illness and Substance Use Disorders in Jails. Fact Sheet Series","author":"National GAINS Center for People With Co-Occuring Disorders in the Justice System","year":"2001"},{"key":"10.1016\/j.schres.2017.05.005_bb0120","series-title":"Schizophrenia: What is Schizophrenia?","author":"National Institute of Mental Health","year":"2016"},{"issue":"2\u20133","key":"10.1016\/j.schres.2017.05.005_bb0125","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.psychres.2009.05.004","article-title":"Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia","volume":"176","author":"Novick","year":"2010","journal-title":"Psychiatry Res."},{"issue":"1","key":"10.1016\/j.schres.2017.05.005_bb0130","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1744-859X-12-32","article-title":"Definitions and drivers of relapse in patients with schizophrenia: a systematic literature review","volume":"12","author":"Olivares","year":"2013","journal-title":"Ann. Gen. Psychiatry."},{"issue":"3","key":"10.1016\/j.schres.2017.05.005_bb0135","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/JCP.0b013e3181dd3103","article-title":"A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia","volume":"30","author":"Pandina","year":"2010","journal-title":"J. Clin. Psychopharmacol"},{"issue":"1","key":"10.1016\/j.schres.2017.05.005_bb0140","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.pnpbp.2010.11.008","article-title":"A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia","volume":"35","author":"Pandina","year":"2011","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2017.05.005_bb0145","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.psychres.2013.08.043","article-title":"Does substance use disorder affect clinical expression in first-hospitalization patients with schizophrenia? Analysis of a prospective cohort","volume":"210","author":"Picci","year":"2013","journal-title":"Psychiatry Res."},{"issue":"2","key":"10.1016\/j.schres.2017.05.005_bb0150","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1001\/archpsyc.1993.01820140007001","article-title":"The de facto US mental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services","volume":"50","author":"Regier","year":"1993","journal-title":"Arch. Gen. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2017.05.005_bb0155","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3109\/13651501.2012.687452","article-title":"Factors associated with relapse in patients with schizophrenia","volume":"17","author":"San","year":"2013","journal-title":"Int. J. Psychiatry Clin. Pract."},{"issue":"Suppl. 20","key":"10.1016\/j.schres.2017.05.005_bb0160","first-page":"22","article-title":"The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59","author":"Sheehan","year":"1998","journal-title":"J. Clin. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2017.05.005_bb0165","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1176\/appi.ajp.2010.10030463","article-title":"Real-time electronic ambulatory monitoring of substance use and symptom expression in schizophrenia","volume":"168","author":"Swendsen","year":"2011","journal-title":"Am. J. Psychiatry"}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996417302645?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996417302645?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,31]],"date-time":"2018-08-31T22:20:04Z","timestamp":1535754004000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996417302645"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":32,"alternative-id":["S0920996417302645"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2017.05.005","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of long-acting and oral antipsychotic treatment effects in patients with schizophrenia, comorbid substance abuse, and a history of recent incarceration: An exploratory analysis of the PRIDE study","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2017.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Janssen Scientific Affairs, LLC. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}